Advancing mRNA-based drug development and vaccine manufacturing

Shared by Parexel experts, Christiane Niederlaender, Cecil Nick, and Sinan Sarac covering on the topics of:

Section 1 - Overview of mRNA Product Manufacturing Challenges
Section 2 - Optimizing the Path to Regulatory Approval for Novel Vaccine
Section 3 - Accelerating Approval of mRNA vaccines for Oncology Drug development

Return to Insights Center

Related Insights

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022

Article

EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022

Video

Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022

Blog

What Do the Next 10 Years Hold for CRISPR?

Jul 27, 2022

Blog

U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022

Blog

SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change

Aug 24, 2022